FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2164290354> ?p ?o ?g. }

• W2164290354 endingPage "1921" @default.
• W2164290354 startingPage "1921" @default.
• W2164290354 abstract "In vitro studies have shown that celecoxib inhibits cyclooxygenase 2 (COX-2) but not COX-1, suggesting that this drug may have anti-inflammatory and analgesic activity without adverse upper gastrointestinal (GI) tract effects that result from COX-1 inhibition.To test whether celecoxib has efficacy as an anti-inflammatory and analgesic with reduced GI tract mucosal damage compared with conventional nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis.Randomized, multicenter, placebo-controlled, double-blind trial lasting 12 weeks, with follow-up at weeks 2, 6, and 12, from September 1996 thorugh February 1998.Seventy-nine clinical sites in the United States and Canada.A total of 1149 patients aged 18 years or older with symptomatic rheumatoid arthritis who met inclusion criteria were randomized; 688 (60%) of these completed the study.Patients were randomized to receive celecoxib, 100 mg, 200 mg, or 400 mg twice per day (n = 240, 235, and 218, respectively); naproxen, 500 mg twice per day (n = 225); or placebo (n = 231).Improvement in signs and symptoms of rheumatoid arthritis as assessed using standard measures of efficacy and GI tract safety as assessed by upper GI tract endoscopy before and after treatment, compared among treatment groups.All dosages of celecoxib and naproxen significantly improved the signs and symptoms of arthritis compared with placebo. Maximal anti-inflammatory and analgesic activity was evident within 2 weeks of initiating treatment and was sustained throughout the 12 weeks. The incidence of endoscopically determined gastroduodenal ulcers in placebo-treated patients was 4 (4%) of 99, and the incidences across all dosages of celecoxib were not significantly different (P>.40): 9 (6%) of 148 with 100 mg twice per day, 6 (4%) of 145 with 200 mg twice per day, and 8 (6%) of 130 with 400 mg twice per day. In contrast, the incidence with naproxen was 36 (26%) of 137, significantly greater than either placebo or celecoxib (P<.001). The overall incidences of GI tract adverse effects were 19% for placebo; 28%, 25%, and 26% for celecoxib 100 mg, 200 mg, and 400 mg twice per day, respectively; and 31 % for naproxen.In this study, all dosages of celecoxib were efficacious in the treatment of rheumatoid arthritis and did not affect COX-1 activity in the GI tract mucosa as evidenced by less frequent incidence of endoscopic ulcers compared with naproxen." @default.
• W2164290354 created "2016-06-24" @default.
• W2164290354 creator A5013044450 @default.
• W2164290354 creator A5017054761 @default.
• W2164290354 creator A5027639379 @default.
• W2164290354 creator A5036550158 @default.
• W2164290354 creator A5043142630 @default.
• W2164290354 creator A5043874873 @default.
• W2164290354 creator A5052221041 @default.
• W2164290354 creator A5053556585 @default.
• W2164290354 creator A5070041052 @default.
• W2164290354 creator A5082669130 @default.
• W2164290354 creator A5084362791 @default.
• W2164290354 date "1999-11-24" @default.
• W2164290354 modified "2023-10-17" @default.
• W2164290354 title "Anti-inflammatory and Upper Gastrointestinal Effects of Celecoxib in Rheumatoid Arthritis" @default.
• W2164290354 cites W1488935046 @default.
• W2164290354 cites W1494920110 @default.
• W2164290354 cites W1601845527 @default.
• W2164290354 cites W186110329 @default.
• W2164290354 cites W1895256094 @default.
• W2164290354 cites W1907103218 @default.
• W2164290354 cites W1964533656 @default.
• W2164290354 cites W1967276177 @default.
• W2164290354 cites W197167335 @default.
• W2164290354 cites W1997208118 @default.
• W2164290354 cites W1997364548 @default.
• W2164290354 cites W2001350224 @default.
• W2164290354 cites W2002263148 @default.
• W2164290354 cites W2003599597 @default.
• W2164290354 cites W2007567412 @default.
• W2164290354 cites W2033255776 @default.
• W2164290354 cites W2033299724 @default.
• W2164290354 cites W2033498682 @default.
• W2164290354 cites W2036268181 @default.
• W2164290354 cites W2038613478 @default.
• W2164290354 cites W2039440412 @default.
• W2164290354 cites W2041776205 @default.
• W2164290354 cites W2054154014 @default.
• W2164290354 cites W2055093350 @default.
• W2164290354 cites W2059340303 @default.
• W2164290354 cites W2059830154 @default.
• W2164290354 cites W2073714032 @default.
• W2164290354 cites W2077285943 @default.
• W2164290354 cites W2081734937 @default.
• W2164290354 cites W2083748640 @default.
• W2164290354 cites W2107833029 @default.
• W2164290354 cites W2113745276 @default.
• W2164290354 cites W2115012618 @default.
• W2164290354 cites W2116959483 @default.
• W2164290354 cites W2134732424 @default.
• W2164290354 cites W2141647944 @default.
• W2164290354 cites W2145382680 @default.
• W2164290354 cites W2146498309 @default.
• W2164290354 cites W2146540723 @default.
• W2164290354 cites W2152348310 @default.
• W2164290354 cites W2159106700 @default.
• W2164290354 cites W2277761139 @default.
• W2164290354 cites W2335752111 @default.
• W2164290354 cites W2339197236 @default.
• W2164290354 cites W2395860939 @default.
• W2164290354 cites W2409808456 @default.
• W2164290354 cites W2488317664 @default.
• W2164290354 cites W2800526221 @default.
• W2164290354 cites W98583635 @default.
• W2164290354 cites W2122138539 @default.
• W2164290354 doi "https://doi.org/10.1001/jama.282.20.1921" @default.
• W2164290354 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10580457" @default.
• W2164290354 hasPublicationYear "1999" @default.
• W2164290354 type Work @default.
• W2164290354 sameAs 2164290354 @default.
• W2164290354 citedByCount "757" @default.
• W2164290354 countsByYear W21642903542012 @default.
• W2164290354 countsByYear W21642903542013 @default.
• W2164290354 countsByYear W21642903542014 @default.
• W2164290354 countsByYear W21642903542015 @default.
• W2164290354 countsByYear W21642903542016 @default.
• W2164290354 countsByYear W21642903542017 @default.
• W2164290354 countsByYear W21642903542018 @default.
• W2164290354 countsByYear W21642903542019 @default.
• W2164290354 countsByYear W21642903542020 @default.
• W2164290354 countsByYear W21642903542021 @default.
• W2164290354 countsByYear W21642903542022 @default.
• W2164290354 countsByYear W21642903542023 @default.
• W2164290354 crossrefType "journal-article" @default.
• W2164290354 hasAuthorship W2164290354A5013044450 @default.
• W2164290354 hasAuthorship W2164290354A5017054761 @default.
• W2164290354 hasAuthorship W2164290354A5027639379 @default.
• W2164290354 hasAuthorship W2164290354A5036550158 @default.
• W2164290354 hasAuthorship W2164290354A5043142630 @default.
• W2164290354 hasAuthorship W2164290354A5043874873 @default.
• W2164290354 hasAuthorship W2164290354A5052221041 @default.
• W2164290354 hasAuthorship W2164290354A5053556585 @default.
• W2164290354 hasAuthorship W2164290354A5070041052 @default.
• W2164290354 hasAuthorship W2164290354A5082669130 @default.
• W2164290354 hasAuthorship W2164290354A5084362791 @default.
• W2164290354 hasBestOaLocation W21642903541 @default.
• W2164290354 hasConcept C126322002 @default.

• next